Schrodinger (SDGR) Jumps: Stock Rises 8.5%

In this article:

Schrodinger, Inc. SDGR was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 16.5% in the past one-month time frame.

The company has seen two positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Schrodinger. So, make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Schrodinger currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Schrodinger, Inc. Price

Schrodinger, Inc. Price
Schrodinger, Inc. Price

Schrodinger, Inc. price | Schrodinger, Inc. Quote

A better-ranked stock in the Medical Info Systems industry is NextGen Healthcare, Inc. NXGN, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks’ Single Best Pick to Double

From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.

The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.

Click Here, See It Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
NEXTGEN HEALTHCARE, INC (NXGN) : Free Stock Analysis Report
 
Schrodinger, Inc. (SDGR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.

Advertisement